Posts Archive

A Phase I Trial of B-cell Maturation Antigen (BCMA) Targeted EGFRt/BCMA-41BBz Chimeric Antigen Receptor (CAR) Modified T Cells With or...

Genetics of Multiple Myeloma for Patients - Rafael Fonseca MD Genetics of Multiple Myeloma for Patients - Rafael Fonseca MD Rafael...

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed...

NCT03012880: Phase 2 - Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple...

BOSTON Study This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and...

NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple...

A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide (DCDP) This is a randomized phase...

Multiple Myeloma Research Consortium NCT03030261: Phase 2: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous...

NCT03309111: Phase 1: ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma Study of ISB 1342, a...

Rafael Fonseca MD - Stem cell transplant for multiple myeloma - for patients Learn More: Rafael Fonseca MD https://www.youtube.com/user/r...

NCT03380039: Phase 1 - Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma A single arm,...

Nature Video: CRISPR: Gene editing and beyond

Dana-Farber Cancer Institute: CAR T-Cell Therapy: How Does It Work? Dana-Farber Cancer Institute - CAR T-Cell Therapy: How Does It Work?...

MUKnineb Study OPTIMUM To determine whether a combination of four novel agents bortezomib(Velcade), lenalidomide (Revlimid), Daratumumab...

KarMMa bb2121 NCT03361748: Phase 2 - Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma...

Modakafusp alfa (Formerly TAK-573) NCT03215030: Phase 1/2: A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics,...

NCT03302403: Phase 1 - Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors...

Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM) Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM) This study...

NCT03336073: Phase 2: GEM-KyCyDex - Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma This is a multicenter, open label,...

MASTER TRIAL Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER) Dara-KRd Monoclonal...

The GRIFFIN trial Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and...

Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the...

Isatuximab in Treating Patients With High Risk Smoldering Plasma Cell Myeloma This phase II trial studies how well isatuximab works in...

NCT02659293: Phase 3: ATLAS Trial: Carfilzomib, Lenalidomide and Dex Vs Lenalidomide Alone After ASCT KRd Vs R NDMM Trial of Carfilzomib,...